Seliciclib - Cyclacel Pharmaceuticals

Drug Profile

Seliciclib - Cyclacel Pharmaceuticals

Alternative Names: CYC 202; R-roscovitine; Seliciclib

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Developer Cedars-Sinai Health System; Cyclacel Pharmaceuticals; University Hospital, Brest; University of Newcastle upon Tyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors; MCL1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Nasopharyngeal cancer; Non-small cell lung cancer; Pituitary ACTH hypersecretion; Rheumatoid arthritis
  • Phase I Solid tumours
  • No development reported Breast cancer
  • Discontinued Glomerulonephritis; Haematological malignancies

Most Recent Events

  • 09 Jan 2018 Phase I development is ongoing for Solid tumours in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO, Capsule)
  • 06 Jun 2016 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumours presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top